PRENDERGAST KENNETH FRANCIS has a total of 14 patent applications. Its first patent ever was published in 1993. It filed its patents most often in United Kingdom, WIPO (World Intellectual Property Organization) and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and micro-structure and nano-technology are BLAZE BIOSCIENCE INC, SCOTT & WHITE HEALTHCARE and SURGIMAB S A S.
# | Country | Total Patents | |
---|---|---|---|
#1 | United Kingdom | 7 | |
#2 | WIPO (World Intellectual Property Organization) | 3 | |
#3 | EPO (European Patent Office) | 2 | |
#4 | United States | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Micro-structure and nano-technology | |
#4 | Medical technology | |
#5 | Environmental technology |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Nanostructure applications | |
#3 | Peptides | |
#4 | Climate change adaptation technologies | |
#5 | Syringes | |
#6 | Diagnosis and surgery | |
#7 | Therapeutic chemical compounds |
# | Name | Total Patents |
---|---|---|
#1 | Prendergast Kenneth Francis | 14 |
#2 | Redpath Trevor Henry | 6 |
Publication | Filing date | Title |
---|---|---|
GB9822737D0 | Pharmaceutical uses of granisetron | |
WO9506737A1 | Glycophorin binding protein (gbp130) fusion compositions | |
GB9412950D0 | Pharmaceutical uses of ondansetron | |
GB9313965D0 | Imaging compositions | |
EP0630407A1 | Anti-viral fusion peptides |